Howard Florey Institute



The Howard Florey Institute, previously known as the Howard Florey Institute of Experimental Physiology and Medicine, is a world-renowned Australian medical and research institute that undertakes clinical and applied research into treatments to combat brain and mind disorders and the cardiovascular system. The institute is based at the University of Melbourne and in 2007 employed 300 staff and students, including many scientists and postgraduate students from overseas.

Areas being researched by scientists include: Parkinson’s disease, stroke, motor neuron disease, traumatic brain and spinal cord injury, addiction, epilepsy, multiple sclerosis, brain development in premature babies, Huntington's disease, depression, schizophrenia, brain function in health and disease, heart failure, and [dementia].

History
The origins of the institute are based on the 1947 ground breaking work of the founder, Dr Derek Denton, and his investigation into the control of salt and water balance in health and disease. The Institute was formally established in 1971 by the Victorian State Government and named after Howard Florey, the Australian Nobel prize winning scientist who developed the manufacture of penicillin. The Institute became a global leader in the scientific areas of: physiological control of body fluid and electrolyte balance, especially the regulation of the adrenal salt-retaining hormone, aldosterone; instincts that control ingestion; and the Relaxin hormone.

As the neuroscience knowledge explosion occurred in the 1990s, the Board made the strategic decision to change the Institute’s focus to brain disorders. Since 1997, eminent neuroscientist, Professor Frederick Mendelsohn AO, has steered the Florey to become Australia’s premiere brain research institute.

Future plans
On 1 July 2007, the legislation that created the Howard Florey Institute of Experimental Physiology and Medicine was repealed, paving the way for the Florey to amalgamate with the Brain Research Institute and the National Stroke Research Institute to become collectively known as the Florey Neuroscience Institutes (FNI).

As part of the amalgamation process, two purpose-built research facilities will be constructed to house the FNI, the Mental Health Research Institute and researchers from the University of Melbourne. This united effort will result in a critical mass of skilled researchers from different disciplines focused exclusively on the brain. A ‘bench to bedside’ research approach will ensure the millions of Australians affected directly and indirectly by brain disorders will benefit from the research undertaken at the FNI.